Journal of Translational Medicine (Feb 2022)

The POR rs10954732 polymorphism decreases susceptibility to hepatocellular carcinoma and hepsin as a prognostic biomarker correlated with immune infiltration based on proteomics

  • Yan Fang,
  • Hongming Yang,
  • Guiming Hu,
  • Jiakun Lu,
  • Jun Zhou,
  • Na Gao,
  • Yuhan Gu,
  • Cunzhen Zhang,
  • Jinhuan Qiu,
  • Yuanyuan Guo,
  • Yunfei Zhang,
  • Qiang Wen,
  • Hailing Qiao

DOI
https://doi.org/10.1186/s12967-022-03282-1
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 17

Abstract

Read online

Abstract The effect of the cytochrome P450 oxidoreductase (POR) rs10954732 (G > A) polymorphism on hepatocellular carcinoma (HCC) susceptibility is unknown. Here we found that A allele carriers showed a 69% decrease in susceptibility to HCC with overall survival (OS) prolonged to 199%, accompanied by lower activity for cytochrome P450 2E1. A total of 222 differentially expressed proteins were mainly enriched in neutrophil and T cell activation and involved in the immune and inflammatory responses, constituting the altered immune tumor microenvironment related with A allele by proteomics analysis. Hepsin (HPN) showed significant down-regulation in HCC and up-regulation in A allele carriers. A lower HPN level was associated with increased susceptibility to HCC and a worse prognosis. Moreover, HPN is a potential independent prognostic biomarker for HCC and is strongly associated with clinicopathological features, tumor-infiltrating status of immune cells both in our discovery cohort and database surveys. Our findings provide a new potential mechanism by which HPN may play an important role in the susceptibility of rs10954732 A allele carriers to HCC and their prognosis through tumor immune infiltration, thus offering potential insights for future studies on tumor immunotherapy.

Keywords